Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Receivables (2020 - 2025)

Biofrontera has reported Receivables over the past 6 years, most recently at $12.1 million for Q4 2025.

  • Quarterly results put Receivables at $12.1 million for Q4 2025, up 13.9% from a year ago — trailing twelve months through Dec 2025 was $12.1 million (up 13.9% YoY), and the annual figure for FY2025 was $12.1 million, up 13.9%.
  • Receivables for Q4 2025 was $12.1 million at Biofrontera, up from $3.0 million in the prior quarter.
  • Over the last five years, Receivables for BFRIW hit a ceiling of $12.1 million in Q4 2025 and a floor of $2.1 million in Q3 2021.
  • Median Receivables over the past 5 years was $5.2 million (2022), compared with a mean of $5.9 million.
  • Biggest five-year swings in Receivables: surged 271.4% in 2022 and later tumbled 53.08% in 2024.
  • Biofrontera's Receivables stood at $3.9 million in 2021, then skyrocketed by 90.68% to $7.4 million in 2022, then increased by 7.51% to $8.0 million in 2023, then soared by 33.32% to $10.6 million in 2024, then rose by 13.9% to $12.1 million in 2025.
  • The last three reported values for Receivables were $12.1 million (Q4 2025), $3.0 million (Q3 2025), and $4.0 million (Q2 2025) per Business Quant data.